Abstract
Bisphosphonates (BPs) are potent antiresorptive agents used to treat osteoporosis and the complications associated with malignant bone metastasis. The aim of this study was to evaluate the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) using the Japanese Adverse Drug Event Report (JADER) database. In particular, we focused on the time-to-onset profile of BRONJ. We analyzed reports of BRONJ in the JADER database and calculated the reporting odds ratio (ROR) of BPs potentially associated with BRONJ. We applied the weibull shape parameter to time-to-event data in JADER. The drugs selected for this investigation were seven BPs approved in Japan (alendronate [intraveneous, I.V.], pamidronate, and zoledronate as I.V. BPs; and alendronate (oral), etidronate, minodronate, and risedronate as oral BPs). We analyzed reports of BRONJ events associated with BPs in the JADER database from April 2004 to November 2014. The median value of BRONJ cases caused by alendronate (I.V.), pamidronate, zoledronate, alendronate (oral), etidronate, minodronate, and risedronate were 1342, 812, 486, 863, 1461, 432, and 730 days, respectively. The lower 95 % confidence interval of the Weibull-shape parameter β for I.V. BPs (pamidronate ...Continue Reading
References
May 1, 1994·British Journal of Clinical Pharmacology·N Baber
May 10, 2002·Pharmacoepidemiology and Drug Safety·Eugène P van PuijenbroekAntoine C G Egberts
May 11, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kathryn L KavanaghUdo Oppermann
Sep 24, 2009·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Joan C LoUNKNOWN Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators
Dec 8, 2009·Australian Endodontic Journal : the Journal of the Australian Society of Endodontology Inc·Salvatore L RuggieroUNKNOWN Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons
Mar 25, 2010·Journal of Bone and Mineral Metabolism·Toshiyuki YonedaMasahiro Urade
Jan 1, 2010·Drug, Healthcare and Patient Safety·Luca Dalle CarbonareMaria Teresa Valenti
Jul 26, 2011·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Masahiro UradeJinichi Fukuta
Oct 12, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F SaadR Dansey
Jun 19, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Victoria R CorneliusStephen J W Evans
May 16, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Odile SauzetVictoria R Cornelius
Aug 2, 2013·Therapeutic Advances in Musculoskeletal Disease·Ieva RuzaUgis Gruntmanis
Feb 5, 2014·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Ryogo UmetsuMitsuhiro Nakamura
Sep 23, 2014·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Salvatore L RuggieroFelice O'Ryan
May 8, 2015·Biological & Pharmaceutical Bulletin·Yukiya SuzukiMitsuhiro Nakamura
Jan 29, 2016·Journal of Pharmaceutical Health Care and Sciences·Yamato KatoMitsuhiro Nakamura
May 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F SaadR Dansey
Citations
Oct 11, 2016·PloS One·Sayaka SasaokaMitsuhiro Nakamura
Jun 2, 2017·Biological & Pharmaceutical Bulletin·Ayako HaraJunko Kizu
Jun 2, 2017·Biological & Pharmaceutical Bulletin·Yugo ChisakiYoshitaka Yano
Feb 1, 2017·Scientific Reports·Xue GongQing Sheng
Jul 22, 2017·PloS One·Shiori HasegawaMitsuhiro Nakamura
May 18, 2018·SAGE Open Medicine·Misa NaganumaMitsuhiro Nakamura
Dec 5, 2017·Biological & Pharmaceutical Bulletin·Satoshi NakaoMitsuhiro Nakamura
Oct 3, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Shiori HasegawaMitsuhiro Nakamura
Aug 11, 2019·Journal of Clinical Pharmacy and Therapeutics·Sayoko KinoshitaMitsutaka Takada
Dec 7, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fusao KomadaKohji Takara
Oct 9, 2019·PloS One·Mizuki TanakaMitsuhiro Nakamura
Sep 2, 2020·Pharmacoepidemiology and Drug Safety·Shiori HasegawaMitsuhiro Nakamura
Jul 22, 2017·Journal of Pharmaceutical Health Care and Sciences·Haruna HatahiraMitsuhiro Nakamura
Feb 2, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fusao Komada
Sep 5, 2017·Biological & Pharmaceutical Bulletin·Mayu TakeyamaYoshiro Saito
Jan 1, 2017·Therapeutic Innovation & Regulatory Science·Yomei Matsuoka, Mamoru Narukawa
Jul 2, 2019·Biological & Pharmaceutical Bulletin·Hideki SugawaraHisamitsu Takase
Jun 23, 2016·Journal of Pharmaceutical Health Care and Sciences·Junko AbeMitsuhiro Nakamura
Feb 6, 2019·Journal of Bone and Mineral Metabolism·Akira TaguchiUNKNOWN Adequate Treatment of Osteoporosis (A-TOP) research group
Sep 11, 2019·Cancer Chemotherapy and Pharmacology·Kazuyo ShimadaMitsuhiro Nakamura
Oct 7, 2017·The Cochrane Database of Systematic Reviews·Natalie H Beth-TasdoganOliver Zolk
Sep 24, 2020·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Guang YangYan Gong
Dec 8, 2020·SAGE Open Medicine·Kiyoka MatsumotoMitsuhiro Nakamura
Feb 16, 2021·Journal of Maxillofacial and Oral Surgery·Sabit Demircan, S Cemil İşler
May 7, 2021·Scientific Reports·Yusuke KanYoshihiro Uesawa